Loading Events

Go Back

event image

Expert Forum on Acute Leukemias – Dallas, TX

May 17 - 18, 2019



  • New developments in chemotherapies and cytotoxic therapies, including liposomal formulations and newly approved antibody drug conjugates.
  • Comparison and integration of agents targeting FLT3 mutations.
  • Emerging clinical developments in epigenetic effector pathways and targets in AML.
  • Targeting apoptosis pathways and tumor suppressor genes for the treatment of AML.
  • Agents in early development of targeted therapies for downstream signaling in AML.
  • Emerging immunotherapies, including CAR-T therapies, in both ALL and AML.
  • Recent developments and standard of care in micro-transplantation.